HIV-1 integrase (HIV-IN) is a well-validated antiviral drug target catalyzing a multistep reaction to incorporate the HIV-1 provirus into the genome of the host cell. Small molecule inhibitors of HIV-1 integrase that specifically target the strand transfer step have demonstrated efficacy in the suppression of virus propagation. However, only few specific strand transfer inhibitors have been identified to date, and the need to screen for novel compound scaffolds persists. Here, the authors describe 2 homogeneous time-resolved fluorescent resonance energy transfer-based assays for the measurement of HIV-1 integrase 3′processing and strand transfer activities. Both assays were optimized for high-throughput screening formats, and a diverse library containing more than 1 million compounds was screened in 1536-well plates for HIV-IN strand transfer inhibitors. As a result, compounds were found that selectively affect the enzymatic strand transfer reaction over 3′ processing. Moreover, several bioactive molecules were identified that inhibited HIV-1 reporter virus infection in cellular model systems. In conclusion, the assays presented herein have proven their utility for the identification of mechanistically interesting and biologically active inhibitors of HIV-1 integrase that hold potential for further development into potent antiviral drugs. (Journal of Biomolecular Screening 2005:456-462) 
INTRODUCTION
I NTEGRASE IS AN ESSENTIAL ENZYME for retroviral replication and an attractive yet unexploited target for the development of novel antiviral drugs against HIV-1 infection and AIDS. [1] [2] [3] [4] HIV-1 integrase (HIV-IN) catalyzes a 2-step reaction preparing for the insertion of provirus DNA into the host genome: 1) In an endonucleolytic 3′-processing (3P) step, HIV-IN removes 2 nucleotides from both ends of the linear viral DNA. This initial processing step is sequence specific and dependent on the recognition of a highly conserved CA-dinucleotide motif in the U3 and U5 regions of the long terminal repeats (LTRs). 2) In the subsequent strand transfer (ST) reaction, HIV-IN first generates a staggered break in the host cell DNA and then covalently ligates the resulting 5′ overhangs with the recessed 3′ ends of the viral LTRs. The resulting "gapped intermediate" product is then further processed by host cell factors to complete the integration of the provirus.
The nucleophilic substitution reactions catalyzed by HIV-IN depend on the presence of divalent metal ions such as Mg 2+ or Mn 2+ in the active site, and HIV-IN inhibitors typically act as chelators of these critical metal ions. [4] [5] [6] [7] It has become apparent over recent years that inhibition of the HIV-IN ST reaction is the primary key to the effective suppression of viral replication in vivo. 8 Small molecules, on the other hand, which inhibit the in vitro activity of HIV-IN by interfering with DNA binding or the 3P reaction alone, generally lack antiviral activity. 8, 9 Among ST inhibitors, 2 series of diketo acids and naphthyridine carboxamides are the most prominent inhibitors of HIV-IN, with demonstrated antiviral activity in cell culture-based HIV proliferation models. 8, [10] [11] [12] Although several compound classes have been found to be active against HIV-IN, 8, [10] [11] [12] [13] none have completed clinical trials so far, mostly because of limited potency or high toxicity. Therefore, the need to screen and to identify new lead structures of HIV-IN inhibitors persists. Traditionally, integrase activities have been measured by low-throughput gel-based assays involving radioactively labeled oligonucleotides. 14, 15 More recently, however, highthroughput screening (HTS)-compatible assays for HIV-IN have been described, among them 1 gel-based assay using microarrayed compound libraries 16 and several microtiter-based solid-phase assays. 8, [17] [18] [19] [20] [21] These solid-phase assays typically monitor the integrase-mediated fusion of an immobilized oligonucleotide mimicking an HIV-1 LTR terminus with a 2nd tagged target oligonucleotide. Product formation is then generally quantified by nonradioactive enzyme-coupled detection strategies. Although microtiter assays are amenable to automation and 96-well platebased screens have been described, 8 solid-phase assays are technically involved and labor intensive because of the necessity for plate coating and plate washing.
Here we describe 2 highly robust homogeneous time-resolved fluorescent resonance energy transfer (TR-FRET)-based assays of the HIV-IN 3P and ST reactions that were optimized for 384well and 1536-well plate formats. A high-throughput screen for HIV-IN ST inhibitors was performed on a 1.36 × 10 6 membered compound library. Consequently, a series of novel HIV-IN inhibitors was found that preferentially inhibit the ST activity of integrase, demonstrate biological activity, and represent interesting starting points for the further development into novel antiviral drugs.
MATERIALS AND METHODS

Materials
LANCE Eu-W8044-labeled streptavidin was purchased from Perkin Elmer (Cat: AD0061). Oligos were purchased from IDT (San Diego, CA): I) 5′ATGTGGAAAATCTCTAGCAGT3′-biot, II) 5′ΑΧΤΓΧΤΑΓΑΓΑΤΤΤΤΧΧΑΧΑΤ3′-Cy5, III) Cy5-5′ATGTGGAAAATCTCTAGCA3′, IV) Cy5-5′ACTGCTAGAG ATTTTCCACAT3′, V) 5′ACAGGCCTAGCACGCGTCG3′-biot, and VI) 5′CGACGCGTGCTAGGCCTGT3′-biot. All other chemicals were from Sigma. For oligonucleotide annealing, oligos I + II (3P substrate), III + IV (ST donor substrate), and V + VI (ST acceptor substrate) were mixed 1:1 at 100 µM in 50 mM Tris (pH 7.6), 10 mM MgCl 2 , heated to 95°C for 20 min, slowly cooled down to room temperature, and stored at -20°C until use.
Protein expression and purification
The clone pINSD.His.Sol was kindly provided by Dr. Robert Craigie (AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health). pINSD.His.Sol expresses a fusion of an N-terminal 6-histidine tag with the F185K and C280S solubility double mutant of full-length HIV-1 integrase 22 on IPTGmediated induction within BL21(DE3) cells (Stratagene, La Jolla, CA).
HIV-1 integrase was expressed as generally described by Lesley and others. 23 Purification was performed by metal ion affinity chromatography after extraction of HIV-IN from the pellet fractions of bacterial lysates under high salt conditions (extraction buffer: 20 mM HEPES, 1 M NaCl, 2 mM β-mercaptoethanol, 5 mM imidazole, pH 7.31). After elution from the Ni-chelate columns (Chelating Sepharose Fast Flow; Pharmacia Biotech Inc., Piscataway, NJ), proteins were dialyzed against a storage buffer (20 mM HEPES, 1 M NaCl, 1 mM DTT, 50 µM ZnSO 4 , 10% glycerol, pH 7.35) and frozen at -80°C.
3P activity assay
3P assays were performed in black solid-bottom 384-well plates (Greiner) in a reaction volume of 25 µl/well (50 µl/well final volume). First, HIV-IN was dispensed at 12.5 µl/well and a concentration of 200 nM in reaction buffer (20 mM Hepes [pH 7.5], 10 mM MnCl 2 , 1 mM DTT, 10% glycerol [w/v], 0.1 mg/ml bovine serum albumin [BSA], 0.05% Brij-35). Then, 500 nl of test compounds or DMSO were added and preincubated with integrase at room temperature for 10 min. Subsequently, the reaction was started by the addition of 12.5 µl/well of the 3P substrate ( Fig. 1 ) at a concentration of 12 nM in reaction buffer. After 3 h of incubation at 37°C, the reaction was stopped by the addition of 25 µl/well Eu-SA conjugate at a concentration of 2 nM in detection buffer (20 mM EDTA, 1 M NaCl, 1 mg/ml BSA, 0.05% Brij-35). TR-FRET signals were measured after 1 h of incubation at room temperature using an Acquest plate reader (Molecular Devices) and the following settings: BB-UV dichroic mirror; excitation, 330 nm; emission for Eu signals, 615 nm; emission for Cy5 signals, 665 nm.
ST activity assay
For assay development, ST assays were performed in black solid-bottom 384-well plates (Greiner) in a reaction volume of 25 µl/well and a final volume of 50 µl/well. The 50-nM ST donor substrate and 200-nM HIV-IN protein were mixed 1:1 in reaction buffer and preincubated on ice for 10 min. The enzyme-substrate mixture was then dispensed into assay plates at 12.5 µl/well, followed by a 500-nl addition of a test compound or DMSO and an additional 10-min incubation at room temperature. The ST reaction was started by the addition of 12.5 µl/well of a 10-nM ST acceptor strand solution in assay buffer and incubated for 2 h at 37°C
. Finally, the detection reagent Eu-SA (25 µl/well, 2 nM in detection buffer) was dispensed, and the plates were kept at room temperature for an additional 3 h. TR-FRET signals were then read using an Acquest plate reader (excitation 330 nm, emission 665/620 nm, dichroic mirror BB-UV).
For HTS purposes, the ST reaction was performed in black solid-bottom 1536-well plates (Greiner) following the same protocol and reagent concentrations as described for the 384-well plate format but using scaled-down volumes (reaction volume of 5 µl/ well and 10 µl/well final volume). Briefly, the ST donor substrate-HIV-IN mixture was dispensed at 2.5 µl/well, compounds were added in 50 nl, the ST acceptor strand was dispensed at 2.5 µl/well, and the detection reagent Eu-SA was dispensed at 5 µl/well. HTR-FRET signals were read by a Viewlux (PerkinElmer) instrument (excitation 330 nm, emission 665/620 nm, dichroic mirror BB-UV).
TR-FRET Assays for HIV-1 Integrase
All Z′ scores were determined as described 24 :
Calculations are based on the standard deviations (STDEV) and intensity means (MEAN) of the controls. For negative controls, 1% DMSO was added to the enzyme reactions. A diketo acid positive control (DAPC) compound was used at a concentration of 10 µM.
Antiviral efficacy assay
Compounds were serially diluted in DMSO and added to adherent HEK293T target cells prior to the addition of the VSV-g pseudotyped HIV-1 luciferase reporter virus (HIV-1 pseudovirions) harvested from 293T producer cells following a triple transient transfection (CaP; Clontech) of the 3 plasmid HIV-1 lentiviral vector system, 25 composed of the VSV-g envelope expression plasmid, packaging construct (delta psi), and the HIV-1 LTR:Luc plasmid. The VSV-g envelope expression plasmid generates the pseudovirus receptor that permits a broad tropism and mediates entry into the 293T target cells. The delta psi packaging construct supplies all of the structural and regulatory gene products needed to generate the pseudovirus. The viral vector RNA synthesized from the HIV-1 LTR:Luc plasmid possesses the cis RNA packaging signal (psi sequence) in addition to the luciferase reporter gene and the HIV-1 LTR. The supernatants of transfected producer cells contain HIV-1 pseudovirions carrying only the luciferase gene in the viral genome. Upon transduction of the target 293T cells, the viral genomic RNA will undergo reverse transcription, nuclear translocation, integration, and transcription of the integrated luciferase gene driven by the PGK (phosphoglycerate kinase promoter). Luciferase activity using Bright-Glo reagent (Promega) substrate was measured 48 h postinfection using a CLIPR plate reader (Molecular Devices) to determine IC 50 values.
RESULTS AND DISCUSSION
Principles of homogeneous assays for HIV-IN 3P and ST reactions
To determine the HIV-IN 3P activity in solution, a 21-mer oligonucleotide was designed to mimic the U5 end of the HIV-1 LTR (modified from Chow 15 ). This 3P substrate was labeled at its 3′ ends with either biotin or the fluorescent dye Cy5, respectively ( Fig. 1A) . Incubation of this substrate with the integrase results in the endonucleolytic removal of a biotinylated dinucleotide 3′ of its CA recognition motif. After termination of the enzyme reaction and binding of SA-Eu chelate constructs to biotinylated nucleotides, TR-FRET pairs form with Cy5 labels on unprocessed substrate molecules. Excitation of the Eu-chelates with UV light leads to light emission at 620 nm, energy transfer to Cy5, and subsequent light emission by Cy5 at 665 nm. Therefore, light emission at 665 nm or, alternatively, the ratio of light emitted at 665 nm and 620 nm is a direct measure for the concentration of unprocessed 3P substrates. A decreasing ratio of light emission at 665 nm and 620 nm over time indicates HIV-IN 3P activity ( Fig. 2A) . For the purposes of compound testing, putative inhibitors of the 3P reaction were preincubated with HIV-IN, and the reaction was started by substrate addition.
To specifically assay the HIV-IN ST activity and to bypass the need for 3P, a preprocessed and merely Cy5-labeled version of the 3P substrate was used as an ST donor substrate (Fig. 1B) . This donor substrate was preincubated with integrase before the addition 15 ). Finally, products of the HIV-IN ST reaction were quantified after SA-Eu addition by determining TR-FRET signals. Each molecule of the Y-shaped fusion product carries 2 Cy5 and SA-Eu molecules in very close proximity, allowing for efficient energy transfer and high sensitivity of the assay. In the case of the ST assay, an increase in the ratio of light emission at 665 nm versus 620 nm over time indicates HIV-IN enzyme activity (Fig. 2B) .
To sensitize the assay for specific ST inhibitors and to bias against compounds that merely interfere with general substrate binding, HIV-IN was preincubated with the ST donor substrate before compound addition. The biotinylated target oligonucleotide was added last to start the enzyme reaction.
In general, TR-FRET-based assays are very resistant to fluorescence interference and are well suited for the screening of diverse chemical libraries containing large numbers of weakly fluorescent compounds. [26] [27] [28] Moreover, due to the normalization step inherent in the ratiometric expression of TR-FRET signals, TR-FRET-based assays yield extremely robust data leading to tight coefficients of variation (CVs) and large Z′ scores. For this reason, the HIV-IN activity assays presented are highly amenable to miniaturization and were found to perform robustly in HTS applications. . Under these reaction conditions, it is likely that only a single round of enzymatic turnover is being monitored before substrate depletion occurs. However, using an excess of enzyme over substrate has been found to be optimal for HIV-IN activity assays by others and is a standard for traditional homogeneous 3P and ST assays involving gel-based autoradiographic detection of product formation. 7, 14, 15, 22 Microtiter-based ST assays typically involve the preformation of enzyme-substrate complexes on the solid phase, and the ratio of proteins bound per ST donor substrate is difficult to assess. Nevertheless, also in microtiter-based ST assays, presumably single turnover events are being monitored.
Development of HIV-IN activity assays
A substantial source of TR-FRET-related background was found to be the concentration of the Eu-labeled ST acceptor substrate. The assay window was maximized by optimizing the substrate concentrations using a 10-fold excess of the ST donor over the ST acceptor substrate. Typically, in a 384-well format, the assay windows after the 3-h reaction time were~2-fold for the 3P reaction and~4-fold for the ST assay ( Figs. 2A, 3A) . Experimental errors were low as a result of internal normalization, with CVs ranging from 1% to 2% and Z′ scores greater than 0.8 for 3P as well as ST assays. The DAPC compound inhibited the 3P reaction with an IC 50 of 1 µM and the ST activity with an IC 50 of 140 nM (Figs.  2B, 3B) . These values compare with an observed cellular efficacy of the DAPC of about an IC 50 of 40 nM (data not shown). The slightly lower apparent activity of the compound in biochemical assays might be explained by the use of an HIV-IN solubility mutant that is known for a low level of resistance toward classical diketo acid inhibitors. [29] [30] [31] 
HTS screen for HIV-IN ST inhibitors and follow-up
In preparation for a high-throughput screen, the ST assay was miniaturized to 5-µl reaction volumes and adapted to suit the 1536well plate format ( Fig. 4 ; see Materials and Methods). Although experimental windows dropped from~4-fold in the 384-well plate format to~2.2-fold, the CVs remained low, ranging from 3.4% in the presence of 10 µM DAPC to 5.6% for the negative DMSO controls. The resulting Z′ scores averaged~0.6, indicating that the robustness of the assay was maintained after miniaturization. The reproducibility of the data is further underlined by interplate comparisons of DAPC titrations (Fig. 4B ). Virtually identical titration curves were obtained on 3 independent assay plates, and the resulting IC 50 values for ST inhibition were found to be 140 nM, in agreement with previous data (Fig. 3B) .
Subsequently, the ST assay was used to screen a total of 1037 1536-well plates containing a total of 1.36 × 10 6 compounds using a customs automated robotics HTS platform. Compounds were tested at a final concentration of 10 µM and considered a hit if they inhibited integrase activity by more than 40%. Hit confirmation and IC 50 determination were performed in the same assay format as the primary screen. As a filter for nonspecific hits in the HIV-IN ST screen (e.g., fluorescence quenchers or biotin derivatives), all primary hits were incubated with 3P substrate in the absence of enzyme. Compounds nonspecifically interfering with the TR-FRET signal obtained after excitation of the nonprocessed 3P substrate were removed from the hit list (data not shown). In summary, 398 primary hits were identified, corresponding to a low 0.03% hit rate. Out of these, 138 compounds (35%) did not reconfirm, 37 compounds (9%)-mostly biotin derivatives-affected the TR-FRET signal nonspecifically, and 223 compounds (56%) specifically inhibited the formation of ST products. These confirmed hits represented a number of different chemical scaffolds including coumarin, polyphenol, and quinone structures, which are known for their inhibitory activity on HIV-IN, 13, 32, 33 besides several novel scaffolds (data not shown).
Next, selected HIV-IN ST inhibitors were tested for their inhibitory potency in the 3P reaction and for their activity in cellular models of HIV-1 proliferation. Figure 5 shows in vitro data for 3 newly identified HIV-IN inhibitors, compounds A-C, as well as DAPC. Compounds A-C inhibit the strand transfer reaction with IC 50 values of about 1 µM ( Fig. 5A ) but do not affect 3P up to 10 µM (Fig. 5B) .
The identification of novel HIV-IN inhibitors showing greater than 10-fold selectivity for ST inhibition versus inhibition of 3P validates our screening strategy. Moreover, it demonstrates the ability of the homogeneous HIV-IN assays to select compounds To evaluate the antiviral efficacy in cells of the newly identified HIV-IN inhibitors, all confirmed hit compounds were tested in HEK293T cells challenged with a VSV-g pseudotyped HIV-1 luciferase reporter virus. This assay will identify inhibitors of early HIV-1 infection events including reverse transcription through integration. As anticipated for an integrase inhibitor, several compounds were found to inhibit HIV-1 reporter virus infection (Table  1) and HIV-1 replication in other cellular models (data not shown). The cellular efficacy of compounds D and E was found to correlate with their activities in the ST assay, suggesting that HIV-IN inhibition is indeed the mechanism for their antiviral activity. Compounds D, E, and F are structurally unrelated. However, their chemistry is consistent with a mechanism of action relying on metal chelation, similar to the mechanism of established diketo acid-type inhibitors of HIV-IN.
CONCLUSION
Two homogeneous TR-FRET-based assays were developed for measuring the 3P and ST activities of HIV-IN. Both assays were readily adapted for screening purposes in the 384-well plate format. The ST assay was further miniaturized and proved to be a solid basis for a high-throughput screen in 1536-well plates. The integrase assays presented here have significant advantages over traditional gel or microtiter-based activity assays. No precoating of the assay plates with enzyme substrate or capture reagents is required, and standard assay plates can be used without previous chemical modification of the plate surfaces. As homogeneous assays, they proved to be easily scaleable to different HTS formats, and with enzyme reactions being performed in solution, loss of enzyme activity as a consequence of immobilization is avoided. The nonradioactive TR-FRET-based detection method is known for its resistance to fluorescence interference from test compounds. Moreover, TR-FRET-based measurements yield highly reproducible data even after miniaturization of reaction volumes. As a result of our screen, several small molecules were found that selectively inhibit the ST activity of HIV-IN without affecting 3P. Moreover, several compounds were found to be active in cellular model systems of HIV-1 proliferation. These compounds represent interesting starting points for a lead optimization effort. In conclusion, the utility of these assays for the identification of mechanistically interesting inhibitors of HIV-IN was demonstrated. 
